Free Trial
→ Elon’s NEXT Big IPO? (From Banyan Hill Publishing) (Ad) Free BCAB Stock Alerts

BioAtla (BCAB) News Today

BioAtla logo
$0.38 -0.02 (-4.45%)
Closing price 07/3/2025 03:06 PM Eastern
Extended Trading
$0.38 0.00 (0.00%)
As of 07/3/2025 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

BCAB Latest News

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
July 3 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/03/3109806/0/en/bioatla-presents-data-from-ongoing-dose-escalation-of-ba3182-dual-conditionally-binding-epcam-x-cd3-bispecific-t-cell-engager-in-patients-with-treatment-refractory-metastatic-adeno.html
BCAB - BioAtla Inc Ordinary Shares Ownership - Morningstar
July 1 at 5:40 PM  |  morningstar.comM
BioAtla Approves 2025 Corporate Bonus Plan
June 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioatla-approves-2025-corporate-bonus-plan?utm_source=marketbeat.com&utm_medium=referral
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma ...
June 3, 2025  |  morningstar.comM
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025
June 2, 2025  |  msn.comhttps://www.msn.com/en-us/science/biology/bioatla-presents-phase-2-oz-v-clinical-trial-data-at-asco-2025/ar-AA1FWiPD
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
June 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/02/3091818/0/en/bioatla-presents-phase-2-ozuriftamab-vedotin-oz-v-clinical-trial-data-demonstrating-compelling-antitumor-activity-in-hpv-associated-oropharyngeal-squamous-cell-carcinoma-hpv-opscc-.html
BioAtla Receives Nasdaq Non-Compliance Notice
May 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioatla-receives-nasdaq-non-compliance-notice?utm_source=marketbeat.com&utm_medium=referral
BioAtla at Citizens JMP Life Sciences: Strategic Partnerships in Focus
May 9, 2025  |  investing.comhttps://www.investing.com/news/transcripts/bioatla-at-citizens-jmp-life-sciences-strategic-partnerships-in-focus-4029551
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
May 6, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4782564-bioatla-inc-bcab-q1-2025-earnings-call-transcript
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
May 6, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/06/3075536/0/en/bioatla-reports-first-quarter-2025-financial-results-and-highlights-recent-progress.html
7BCAB : A Preview Of BioAtla's Earnings
May 5, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/05/45206199/a-preview-of-bioatlas-earnings
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
May 1, 2025  |  seekingalpha.comhttps://seekingalpha.com/pr/20082376-bioatla-to-announce-first-quarter-2025-financial-results-and-provide-business-highlights-on
BioAtla to Participate in the Citizens Life Sciences Conference
April 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/30/3071256/0/en/bioatla-to-participate-in-the-citizens-life-sciences-conference.html
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
April 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/29/3070121/0/en/bioatla-to-announce-first-quarter-2025-financial-results-and-provide-business-highlights-on-may-6-2025.html
BioAtla announces poster presentations at 2025 AACR meeting
April 24, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-announces-poster-presentations-at-2025-aacr-meeting-1034621503
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/24/3067329/0/en/bioatla-announces-poster-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting.html
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/23/3066554/0/en/bioatla-announces-upcoming-poster-presentation-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting.html
H.C. Wainwright Keeps Their Hold Rating on BioAtla (BCAB)
March 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/h-c-wainwright-keeps-their-hold-rating-on-bioatla-bcab-1034532843
BioAtla price target lowered to $1 from $5 at Citizens JMP
March 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-price-target-lowered-to-1-from-5-at-citizens-jmp-1034532940
BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript
March 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/bioatla-inc-nasdaqbcab-q4-2024-earnings-call-transcript/ar-AA1BTFR7
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises
March 28, 2025  |  uk.investing.comhttps://uk.investing.com/news/transcripts/earnings-call-transcript-bioatla-q4-2024-sees-strategic-cost-cuts-stock-rises-93CH-4001868
BioAtla price target lowered to $10 from $13 at BTIG
March 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-price-target-lowered-to-10-from-13-at-btig-1034527169
BioAtla announces restructuring, to cut over 30% of workforce
March 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-announces-restructuring-to-cut-over-30-of-workforce-1034523931
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
March 27, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4771064-bioatla-inc-bcab-q4-2024-earnings-call-transcript
BioAtla Cuts 30% of Jobs in Restructuring Effort
March 27, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/bioatla-cuts-30-of-jobs-in-restructuring-effort-bf2d8628
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
March 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/27/3050994/0/en/BioAtla-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Highlights-Recent-Progress.html
Earnings Outlook For BioAtla
March 27, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/03/44500121/earnings-outlook-for-bioatla
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
March 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/20/3046153/0/en/bioatla-announces-two-poster-presentations-at-upcoming-medical-meetings.html
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
March 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/19/3045312/0/en/bioatla-to-announce-fourth-quarter-and-full-year-2024-financial-results-and-provide-business-highlights-on-march-27-2025.html
AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)
March 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/04/3036395/28124/en/axl-inhibitors-pipeline-research-report-2025-features-insights-on-16-companies-and-20-pipeline-drugs-including-cabozantinib-exelixis-ipsen-ba-3011-bioatla-tp-0903-sumitomo-dainippo.html
BioAtla faces Nasdaq delisting over share price rule
February 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/bioatla-faces-nasdaq-delisting-over-share-price-rule/ar-AA1yCw2Q
BioAtla Secures $9.2M for Clinical Program Advancements
December 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-secures-9-2m-for-clinical-program-advancements-1034164462
BioAtla Highlights Advancements in CAB Cancer Therapy
December 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-highlights-advancements-in-cab-cancer-therapy-1034163113
BioAtla to sell 9.68M shares at 95.2c in registered direct offering
December 20, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-to-sell-9-68m-shares-at-95-2c-in-registered-direct-offering-1034163005
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
December 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/20/3000632/0/en/bioatla-inc-announces-registered-direct-offering-to-advance-two-mid-stage-clinical-programs-to-key-inflection-points.html
BioAtla presents data on mecbotamab vedotin in advanced NSCLC
December 17, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-presents-data-on-mecbotamab-vedotin-in-advanced-nsclc-1034141695
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
December 16, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/16/2997463/0/en/bioatla-presented-data-characterizing-mutated-kras-genotype-and-clinical-outcomes-in-patients-with-advanced-nsclc-treated-with-mecbotamab-vedotin-mec-v-a-cab-axl-adc-at-the-iaslc-2.html
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
December 10, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/10/2994467/0/en/bioatla-announces-upcoming-poster-presentation-at-the-iaslc-2024-hot-topic-in-basic-translational-science-meeting.html
GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB)
November 19, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsa-capital-partners-llp-purchases-new-position-in-bioatla-inc-nasdaqbcab-2024-11-19/
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 7.1% in October
November 18, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bioatla-inc-nasdaqbcab-short-interest-down-71-in-october-2024-11-18/
FY2024 Earnings Forecast for BioAtla Issued By HC Wainwright
November 15, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/fy2024-earnings-forecast-for-bioatla-issued-by-hc-wainwright-2024-11-15/
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades
November 14, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/michael-burrys-scion-fund-exits-bioatla-boosts-alibaba-stake-adds-puts-top-q3-trades/ar-AA1u5WAG
BioAtla: Strong Financials and Promising Clinical Progress Drive Buy Rating
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-strong-financials-and-promising-clinical-progress-drive-buy-rating-1034006395
HC Wainwright & Co. Downgrades BioAtla (BCAB)
November 14, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-bioatla-bcab/ar-AA1u3amf
BioAtla (BCAB) was downgraded to a Hold Rating at H.C. Wainwright
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-bcab-was-downgraded-to-a-hold-rating-at-h-c-wainwright-1034008508
HC Wainwright Downgrades BioAtla (NASDAQ:BCAB) to Neutral
November 13, 2024  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-downgrades-bioatla-nasdaqbcab-to-neutral-2024-11-13/
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript
November 12, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/bioatla-inc-nasdaqbcab-q3-2024-earnings-call-transcript/ar-AA1tSy85
BioAtla Reports Q3 2024 Financial Results and Clinical Advances
November 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/bioatla-reports-q3-2024-financial-results-and-clinical-advances-1033980328
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
November 9, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/bioatla-inc-bcab-q3-2024-210356605.html
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
November 9, 2024  |  seekingalpha.comhttps://seekingalpha.com/article/4735466-bioatla-inc-bcab-q3-2024-earnings-call-transcript
Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.

BCAB Media Mentions By Week

BCAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCAB
News Sentiment
▼
0.30

0.54
▲
Average
Medical
News Sentiment

BCAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCAB Articles
This Week
▼
2

1
▲
BCAB Articles
Average Week

Get BioAtla News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:BCAB) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
379 passengers walked away from this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
Crypto Is Pumping Again – Now Comes the Real Opportunity
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Gold: Now legal tender in many states
The perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...
Stansberry Research | Sponsored